120 related articles for article (PubMed ID: 37846469)
21. Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study.
Xu R; Yu X; Hao J; Wang L; Pan H; Han G; Xu J; Zhang Y; Yang S; Chen J; Ying J; Dai G; Li M; Begic D; Lu B; Shen L
BMC Cancer; 2017 Dec; 17(1):885. PubMed ID: 29273007
[TBL] [Abstract][Full Text] [Related]
22. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
Front Immunol; 2022; 13():946861. PubMed ID: 35967452
[TBL] [Abstract][Full Text] [Related]
23. Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial.
Huffman BM; Basu Mallick A; Horick NK; Wang-Gillam A; Hosein PJ; Morse MA; Beg MS; Murphy JE; Mavroukakis S; Zaki A; Schlechter BL; Sanoff H; Manz C; Wolpin BM; Arlen P; Lacy J; Cleary JM
JAMA Netw Open; 2023 Jan; 6(1):e2249720. PubMed ID: 36602796
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine, Cisplatin, and Nab-Paclitaxel as a First-Line Therapy for Advanced Biliary Tract Cancers.
Gedela S; Munot P; Vaidyanathan A; Joarder R; Chaugule D; Parulekar M; Nashikkar C; Ghadi A; Vadodaria D; Goel M; Patkar S; Mandavkar S; Ramaswamy A; Bhargava P; Srinivas S; Ostwal V
J Gastrointest Cancer; 2024 Mar; 55(1):263-269. PubMed ID: 37368175
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical study.
Zhang J; Pan Y; Shi Q; Zhang G; Jiang L; Dong X; Gu K; Wang H; Zhang X; Yang N; Li Y; Xiong J; Yi T; Peng M; Song Y; Fan Y; Cui J; Chen G; Tan W; Zang A; Guo Q; Zhao G; Wang Z; He J; Yao W; Wu X; Chen K; Hu X; Hu C; Yue L; Jiang D; Wang G; Liu J; Yu G; Li J; Bai J; Xie W; Zhao W; Wu L; Zhou C
Cancer Commun (Lond); 2022 Jan; 42(1):3-16. PubMed ID: 34699693
[TBL] [Abstract][Full Text] [Related]
26. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
Rimini M; Masi G; Lonardi S; Nichetti F; Pressiani T; Lavacchi D; Jessica L; Giordano G; Scartozzi M; Tamburini E; Pastorino A; Rapposelli IG; Daniele B; Martinelli E; Garajova I; Aprile G; Schirripa M; Formica V; Salani F; Winchler C; Bergamo F; Balsano R; Gusmaroli E; Lorenzo A; Landriscina M; Pretta A; Toma I; Pirrone C; Diana A; Leone F; Brunetti O; Brandi G; Garattini SK; Satolli MA; Rossari F; Fornaro L; Niger M; Zanuso V; De Rosa A; Ratti F; Aldrighetti L; De Braud F; Foti S; Rizzato MD; Vivaldi C; Stefano C; Rimassa L; Antonuzzo L; Casadei-Gardini A
Target Oncol; 2024 May; 19(3):359-370. PubMed ID: 38691295
[TBL] [Abstract][Full Text] [Related]
27. A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study.
Chang C; Meng L; Li X; Cheng K; Yi C; Peng B; Ma J; Cao D
Cancer Control; 2022; 29():10732748221141233. PubMed ID: 36423238
[TBL] [Abstract][Full Text] [Related]
28. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study.
Tempero M; Oh DY; Tabernero J; Reni M; Van Cutsem E; Hendifar A; Waldschmidt DT; Starling N; Bachet JB; Chang HM; Maurel J; Garcia-Carbonero R; Lonardi S; Coussens LM; Fong L; Tsao LC; Cole G; James D; Macarulla T
Ann Oncol; 2021 May; 32(5):600-608. PubMed ID: 33539945
[TBL] [Abstract][Full Text] [Related]
29. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
Rinaldi Y; Pointet AL; Khemissa Akouz F; Le Malicot K; Wahiba B; Louafi S; Gratet A; Miglianico L; Laharie H; Bouhier Leporrier K; Thirot Bidault A; Texereau P; Coriat R; Terrebonne E; Gouttebel MC; Malka D; Bachet JB; Lepage C; Taieb J;
Eur J Cancer; 2020 Sep; 136():25-34. PubMed ID: 32623182
[TBL] [Abstract][Full Text] [Related]
31. Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer.
Ueno H; Ikeda M; Ueno M; Mizuno N; Ioka T; Omuro Y; Nakajima TE; Furuse J
Cancer Chemother Pharmacol; 2016 Mar; 77(3):595-603. PubMed ID: 26842789
[TBL] [Abstract][Full Text] [Related]
32. Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis.
Schlick K; Gantschnigg A; Seymer A; Huemer F; Greil R; Weiss L
Cancer Med; 2023 Aug; 12(16):16997-17004. PubMed ID: 37537780
[TBL] [Abstract][Full Text] [Related]
33. Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis.
Cheon J; Lee CK; Sang YB; Choi HJ; Kim MH; Ji JH; Ko KH; Kwon CI; Kim DJ; Choi SH; Kim C; Kang B; Chon HJ
Ther Adv Med Oncol; 2021; 13():17588359211035983. PubMed ID: 34394748
[TBL] [Abstract][Full Text] [Related]
34. A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer.
Hattori Y; Kono Y; Itoh S; Inoue T; Urata Y; Kawa Y; Tohnai R; Kumagai T; Nishino K; Uozumi R; Morita S; Negoro S; Imamura F; Satouchi M
BMC Cancer; 2020 Feb; 20(1):115. PubMed ID: 32046667
[TBL] [Abstract][Full Text] [Related]
35. Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study.
Rivera F; Benavides M; Gallego J; Guillen-Ponce C; Lopez-Martin J; Küng M
Pancreatology; 2019 Jan; 19(1):64-72. PubMed ID: 30396819
[TBL] [Abstract][Full Text] [Related]
36. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data.
Rimini M; Fornaro L; Lonardi S; Niger M; Lavacchi D; Pressiani T; Lucchetti J; Giordano G; Pretta A; Tamburini E; Pirrone C; Rapposelli IG; Diana A; Martinelli E; Garajová I; Simionato F; Schirripa M; Formica V; Vivaldi C; Caliman E; Rizzato MD; Zanuso V; Nichetti F; Angotti L; Landriscina M; Scartozzi M; Ramundo M; Pastorino A; Daniele B; Cornara N; Persano M; Gusmaroli E; Cerantola R; Salani F; Ratti F; Aldrighetti L; Cascinu S; Rimassa L; Antonuzzo L; Casadei-Gardini A
Liver Int; 2023 Aug; 43(8):1803-1812. PubMed ID: 37452505
[TBL] [Abstract][Full Text] [Related]
37. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
Reni M; Zanon S; Balzano G; Passoni P; Pircher C; Chiaravalli M; Fugazza C; Ceraulo D; Nicoletti R; Arcidiacono PG; Macchini M; Peretti U; Castoldi R; Doglioni C; Falconi M; Partelli S; Gianni L
Eur J Cancer; 2018 Oct; 102():95-102. PubMed ID: 30149366
[TBL] [Abstract][Full Text] [Related]
38. Phase I/II Study of Cisplatin plus Nab-Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer.
Hayashi H; Ogura M; Niwa T; Yokoyama T; Tanizaki J; Ozaki T; Yoshioka H; Kurata T; Tamura Y; Fujisaka Y; Tanaka K; Hasegawa Y; Kudo K; Chiba Y; Nakagawa K
Oncologist; 2021 Jan; 26(1):19-e52. PubMed ID: 32918791
[TBL] [Abstract][Full Text] [Related]
39. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
Zong Y; Yuan J; Peng Z; Lu M; Wang X; Shen L; Zhou J
J Cancer Res Clin Oncol; 2021 May; 147(5):1529-1536. PubMed ID: 33191450
[TBL] [Abstract][Full Text] [Related]
40. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
Yardley DA; Coleman R; Conte P; Cortes J; Brufsky A; Shtivelband M; Young R; Bengala C; Ali H; Eakel J; Schneeweiss A; de la Cruz-Merino L; Wilks S; O'Shaughnessy J; Glück S; Li H; Miller J; Barton D; Harbeck N;
Ann Oncol; 2018 Aug; 29(8):1763-1770. PubMed ID: 29878040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
